SMS Pharmaceuticals Ltd
SMS Pharmaceuticals Ltd, a prominent player in the pharmaceutical industry, is headquartered in India and operates extensively across various regions. Founded in 1987, the company has established itself as a leader in the production of active pharmaceutical ingredients (APIs) and formulations, catering to both domestic and international markets. With a diverse portfolio that includes anti-infectives, anti-diabetics, and cardiovascular medications, SMS Pharmaceuticals is recognised for its commitment to quality and innovation. The company’s state-of-the-art manufacturing facilities adhere to stringent regulatory standards, ensuring the delivery of high-quality products. Notable achievements include successful collaborations with global pharmaceutical firms and a strong market presence in Europe and the Americas. SMS Pharmaceuticals Ltd continues to drive advancements in healthcare, making significant contributions to the pharmaceutical landscape.
DitchCarbon Score
How does SMS Pharmaceuticals Ltd's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
SMS Pharmaceuticals Ltd's score of 10 is higher than 69% of the industry. This can give you a sense of how well the company is doing compared to its peers.
SMS Pharmaceuticals Ltd's reported carbon emissions
In 2023, SMS Pharmaceuticals Ltd reported total carbon emissions of approximately 32,757,700 kg CO2e, comprising 32,757,700 kg CO2e from Scope 1, 28,551,170 kg CO2e from Scope 2, and 31,870 kg CO2e from Scope 3. This represents a slight increase in Scope 1 emissions compared to 2022, where they were about 25,759,670 kg CO2e, while Scope 2 emissions decreased from approximately 31,505,800 kg CO2e in the previous year. Looking ahead to 2024, the company anticipates further increases in emissions, with projected figures of approximately 37,382,480 kg CO2e for Scope 1 and 42,378,970 kg CO2e for Scope 2, alongside a notable rise in Scope 3 emissions to about 200,610 kg CO2e. Despite these figures, SMS Pharmaceuticals Ltd has not disclosed any specific reduction targets or initiatives aimed at mitigating their carbon footprint. The absence of defined climate commitments or science-based targets suggests a need for enhanced strategies to address their emissions and align with industry standards for sustainability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 25,759,670 | 00,000,000 | 00,000,000 |
| Scope 2 | 31,505,800 | 00,000,000 | 00,000,000 |
| Scope 3 | 32,500 | 00,000 | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
SMS Pharmaceuticals Ltd is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
